NaviFUS (ROCO:6872) FCF Margin % : -1,013.05% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NaviFUS FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NaviFUS's Free Cash Flow for the six months ended in Jun. 2024 was NT$-52.17 Mil. NaviFUS's Revenue for the six months ended in Jun. 2024 was NT$5.15 Mil. Therefore, NaviFUS's FCF Margin % for the quarter that ended in Jun. 2024 was -1,013.05%.

As of today, NaviFUS's current FCF Yield % is -5.43%.

The historical rank and industry rank for NaviFUS's FCF Margin % or its related term are showing as below:

ROCO:6872' s FCF Margin % Range Over the Past 10 Years
Min: -1324.17 Med: -404.93 Max: -392.05
Current: -1324.17

During the past 6 years, the highest FCF Margin % of NaviFUS was -392.05%. The lowest was -1324.17%. And the median was -404.93%.

ROCO:6872's FCF Margin % is ranked worse than
77.22% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs ROCO:6872: -1324.17

NaviFUS FCF Margin % Historical Data

The historical data trend for NaviFUS's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS FCF Margin % Chart

NaviFUS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-417.80

-392.05

NaviFUS Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial						-343.78	-561.40	-210.29	-2,042.69	-1,013.05

Competitive Comparison of NaviFUS's FCF Margin %

For the Biotechnology subindustry, NaviFUS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NaviFUS's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NaviFUS's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NaviFUS's FCF Margin % falls into.

NaviFUS FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NaviFUS's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-88.137	/	22.481
	=	-392.05 %

NaviFUS's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-52.172	/	5.15
	=	-1,013.05 %

NaviFUS FCF Margin % Related Terms

Thank you for viewing the detailed overview of NaviFUS's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NaviFUS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103

Website

https://www.navifus.com

NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS Headlines

No Headlines